Ipsen delivers solid sales growth year-to-date

30 October 2023
ipsen_france_large

French drugmaker Ipsen (Euronext: IPN) has presented its sales performance for the year-to-date 2023.

Total sales for the nine months rose 4.6% to 2.31 billion euros ($2.44 billion), or 7.1% at constant exchange rates.

Within this, oncology product revenues down 1.3% at 1.74 billion euros (+0.8% at CER). Neurosciences sales shot up 19.9% to 489 million euros (+24.5% at CER), and rare diseases sales were unchanged at 76 million euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical